INTUSOMICS ANALYTICS
Contact information
- Biomarkers
- Drug discovery
- Screening
- Cosmetics
- Dermatology
- Genetic and rare diseases
- Immunology
- Oncology
- Other enhancement techniques (molecular marker..)
- Microorganism
- Bioinformatics
- Genomics
- Metabolomics
- Proteomics
- CRO / CMO / SMO
Intusomics is a CRO specialized in advanced bioinformatics and high-value translational biology. We help hospitals, research centers, and biotechnology and pharmaceutical companies turn complex omics data into actionable biological results, biomarkers, robust hypotheses, and useful decisions for development, validation, and publication. Our mission is to recover the real biological signal that automated pipelines often miss and turn it into knowledge with translational, clinical, strategic, and commercial impact.
NGS and multi-omics analysis: genomics (WES/WGS), bulk transcriptomics and single-cell RNA-seq, and multi-omics integration with metagenomics, proteomics, and metabolomics to extract biological signal with translational value.
Microbiome, metagenomics, and resistance profiling: 16S and shotgun analysis for taxonomic and functional profiling, resistome analysis (antimicrobial resistance genes), pathogen detection, microbial biomarkers, and in silico discovery of antimicrobial peptides (AMPs).
Statistical consulting and experimental design: sample size, power analysis, customized models, and analysis plans tailored to each biological hypothesis and development objective.
Biomarkers and therapeutic targets: in silico discovery and validation, drug repositioning, and co-development of IP, licenses, and new biotechnology assets.
Proprietary technology: advanced batch effect correction, proprietary microRNA profiling, and AI/Deep Learning applied to biological networks, signatures, and prioritization of findings.
From data to assets: biological interpretation and scientific support to turn results into publications, biomarkers, patents, licenses, and new development opportunities.
NGS and multi-omics analysis: genomics (WES/WGS), bulk transcriptomics and single-cell RNA-seq, and multi-omics integration with metagenomics, proteomics, and metabolomics to extract biological signal with translational value.
Microbiome, metagenomics, and resistance profiling: 16S and shotgun analysis for taxonomic and functional profiling, resistome analysis (antimicrobial resistance genes), pathogen detection, microbial biomarkers, and in silico discovery of antimicrobial peptides (AMPs).
Statistical consulting and experimental design: sample size, power analysis, customized models, and analysis plans tailored to each biological hypothesis and development objective.
Biomarkers and therapeutic targets: in silico discovery and validation, drug repositioning, and co-development of IP, licenses, and new biotechnology assets.
Proprietary technology: advanced batch effect correction, proprietary microRNA profiling, and AI/Deep Learning applied to biological networks, signatures, and prioritization of findings.
From data to assets: biological interpretation and scientific support to turn results into publications, biomarkers, patents, licenses, and new development opportunities.